LEX Diagnostics is pioneering a rapid PCR molecular diagnostic system designed for point-of-care testing, significantly enhancing the speed and sensitivity of diagnostic results. Their innovative technology allows for the detection and differentiation of respiratory viruses, including Flu A, Flu B, and COVID-19, with positive results available in as little as five minutes and negative results in under ten minutes. The system is tailored for CLIA waived settings, featuring a fully automated workflow that eliminates the need for liquid sample handling, thereby reducing the risk of infection and saving valuable time during patient appointments. LEX Diagnostics aims to expand its testing capabilities to include additional respiratory tests and sexually transmitted infections in future iterations of their technology.

Central to LEX Diagnostics' rapid testing capabilities is their patented thermal cycler technology, which replaces traditional Peltier devices with a more efficient heating and cooling mechanism. This advancement allows for precise thermal control, enabling faster PCR diagnostics while maintaining high sensitivity. The system utilizes proprietary LEX reagents and a direct-to-PCR workflow, which collectively contribute to lower costs and improved reliability compared to existing molecular diagnostic tests. The user-friendly design of the LEX system incorporates a cartridge that accepts a dry swab, streamlining the sample preparation and processing steps, thus minimizing hands-on time for healthcare professionals and enhancing the overall efficiency of point-of-care testing.

United Kingdom

LEX Diagnostics is a privately held molecular diagnostics company developing products designed to enhance patient care by delivering clinical insights within minutes and at the time they are most valuable. Delivering a high-speed molecular test will redefine point-of-care diagnostics.

LEX Diagnostics

Company Details